flexion therapeutics buyout

To receive more information regarding the investigation of Flexion Therapeutics, Inc. please fill out the form below. Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc., Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. (incorporated by reference to the Company's Current Report on Form 8-K filed with the SEC on October 12, 2021). We anticipate full-year 2021 ZILRETTA sales in the range of $120 million to $130 . Pacira BioSciences to Acquire Flexion Therapeutics Further ... Pacira Beefs Up Non-Opioid Pain Management Via Flexion ... Assuming it doesn't get a buyout bid first. Flexion Therapeutics (Nasdaq: FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), , the most common form of arthritis. Shares of the Flexion Therapeutics, Inc. (FLXN) stock were popping high today on October 11, 2021, following the announcement of its acquisition by Pacira. FLXN is long from an average price of $18.75. Oct 11, 2021. First/Last Name. They focus on drug manufacturing, and they discover and develop drugs for neurologic diseases in the United States. Source: Flexion Therapeutics, Inc. Adamas Pharmaceuticals. Beam Therapeutics is developing precision genetic medicines through the use of base editing. However the probability of a buyout has lessened based on recent developments. Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management Provided by GlobeNewswire Nov 19, 2021 1:40 PM UTC Pacira BioSciences, Inc. completed the acquisition of Flexion Therapeutics, Inc.. Pacira BioSciences, Inc. (NasdaqGS:PCRX) entered into a definitive Agreement and Plan of Merger to acquire Flexion Therapeutics, Inc. (NasdaqGM:FLXN) for approximately $440 million on October 11, 2021. Exhibits. Flexion Therapeutics, Inc. (NASDAQ:FLXN) was the recipient of a large growth in short interest during the month of October. FLXN stock price saw an uptrend of 61.76% to reach $9.35 a share at the time of this writing. Pacira BioSciences, the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. announced a definitive agreement pursuant to which Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash. The deal represents a roughly 47% premium . TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (Nasdaq: FLXN) today announced a definitive agreement pursuant to which Pacira will . "Zilretta is a highly complementary commercial asset that allows us to provide physicians with another tool in their pain management armamentarium . The Floridian biotech Pacira BioSciences Inc. is shelling out $500 million to acquire Burlington drugmaker Flexion Therapeutics Inc. Pacira (Nasdaq: PCRX) will pay $8.50 for each . Current Price: $0.77 (CVR only) Offer Price: $3.70 Upside: 380% Expiration Date: December 2030 This idea was shared by Joshua. The reduct If you are a shareholder of Flexion and believe the proposed buyout price is too low or you're interested in learning more about the investigation, please contact lead analyst Jim Baker (jimb . Flexion Therapeutics (Nasdaq:FLXN) is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA, a type of degenerative arthritis. Shares of Flexion Therapeutics surged on Monday after it agreed to be bought by Pacira BioSciences in a $427.5m deal. Stockholders will receive $8.50 and one contingent value right worth up to $8.00 for each share of Flexion Therapeutics stock that they hold. Credit: Marco Verch Professional Photographer / Flickr. A company's changing earnings picture is at the core of the Zacks rating. I provide a brief background on Pacira BioSciences and some of the details of the deal. Deciphera Pharmaceuticals Inc. (Nasdaq: DCPH) announced plans to let go 140 people, while Flexion Therapeutics Inc., after its acquisition by Pacira BioSciences Inc. (Nasdaq: PCRX), said it would . Flexion acquisition is expected to be accretive to full-year 2022 earnings and significantly accretive after that. The subsequent on Behalf of the Person Filing Statement) Consider taking profits and exiting in the zone of $22 to $24.38. The trading volume as of now was 12,528,840, far h The company stated that the combined portfolio helps in providing end-to-end non-opioid solutions along the neural pain pathway. Flexion's lead product, Zilretta, is used for osteoarthritic knee pain. 22:27 07/12/21. Rowley Law PLLC is investigating potential securities law violations by Flexion Therapeutics, Inc. (NASDAQ: FLXN) and its board of directors concerning the proposed acquisition of the company by Pacira BioSciences, Inc. (NASDAQ: PCRX). The transaction is expected to close in the fourth . Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management Published: Nov. 19, 2021 at 8:40 a.m. Fresh off the closing of its acquisition by Tampa, Florida-based Pacira BioSciences Inc., Flexion Therapeutics Inc. has notified the state that it plans to lay off 153 employees — 43 of them in . Flexion Therapeutics is a biopharmaceutical company focused on advancing innovative, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. FLEXION THERAPEUTICS INC : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of . Under the terms of the merger agreement, Pacira will commence a tender offer to . Flexion Therapeutics recently announced that they have agreed to be acquired by Pacira BioSciences for $8.50 a share bid with the potential for an extra $8 from CVR. Flexion's Zilretta (triamcinolone acetonide extended-release injectable suspension), a treatment for . The company will acquire Flexion for an equity value of nearly $450m or $630m, which includes debt. Pros. Pacira BioSciences Inc. on Monday said it agreed to buy fellow drugmaker Flexion Therapeutics Inc. for an initial $427 million, or $8.50 a share, in cash. Flexion Therapeutics Scott Young, (781) 305-7194 syoung@flexiontherapeutics.com. Flexion Therapeutics (NASDAQ: FLXN) is joining the pack of . FLEXION THERAPEUTICS, INC. (Name of Subject Company (Issuer)) Oyster Acquisition Company Inc. (Offeror) a wholly owned subsidiary of . PACIRA BIOSCIENCES, INC. (Parent of Offeror) (Names of Filing Persons) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 33938J106 (CUSIP Number of Class of Securities) David Stack I discuss my opinion about some of the positive and negative aspects of the deal. Pacira Biosciences completed its acquisition of Flexion Therapeutics, according to a Nov. 19 news release.. Pacira Biosciences signed the agreement for the acquisition Oct. 11. Flexion Therapeutics (Nasdaq: FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal . Flexion has one drug currently on the market, Zilretta, which is an . Free forex prices, toplists, indices and lots more. The investigation focuses on whether Flexion Therapeutics, Inc. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a . About Flexion Therapeutics. She has more than 25 years of human resources and leadership development experience ranging from small start-ups to Fortune 500 companies spanning the Pharmaceutical/Biotech, Aerospace, Internet, IT and Management Consulting and Retail industries. Interest expense was $5.2 million and $4.7 million for the three months ended March 31, 2021 and 2020 respectively. Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management. About Flexion Therapeutics. Burlington, MA 01803 (781) 305-7777 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications. Flexion Therapeutics, Inc. (FLXN) relating to its proposed acquisition by Pacira BioSciences, Inc. Under the terms of the agreement, FLXN shareholders will receive $8.50 in cash per share they own. Situation Overview On Monday October 11, 2021, Pacira Biosciences announced that it would be acquiring Flexion Therapeutics valuing the equity at $450m on a fully diluted basis and an EV of ~$550m. It specializes in treatment of patients with musculoskeletal conditions including osteoarthritis, a type of degenerative arthritis. Subject: Flexion Therapeutics, Inc. - Cash Settlement/Acceleration of Expirations Option Symbol: FLXN Date: 11/19/21 On November 18, 2021, Oyster Acquisition Company Inc., a wholly owned subsidiary of Pacira BioSciences, Inc., completed its tender offer for Flexion Therapeutics, Inc. (FLXN). Disclosure: Author is Long NBIX, ENTA, PTLA . Flexion Therapeutics, Inc. 10 Mall Road, Suite 301. Sanofi is in talks to buy Flexion Therapeutics, a Boston-area biotech with its lead product now awaiting FDA approval, for more than $1 billion in cash, according to a source close to the deal. 1:21-cv-08693.The second complaint was filed on October 28, 2021 . $0.00. Stockholders will receive $8.50 and one contingent value right worth up to $8.00 for each share of Flexion Therapeutics stock that they hold. Under the merger agreement, Pacira will commence a tender . Through the acquisition, Pacira will also get access to Flexion's two more drugs, FX201 and FX301, which aim to treat musculoskeletal pain and postsurgical pain, respectively. The transaction will close in Q4 of 2021. Stockholders will receive $8.50 and one contingent value right worth up to $8.00 for each share of Flexion . It is trading at $22.31 as of this writing. TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE . " Upper management does not know the marketplace " (in 4 reviews) " There is no downsides to working at Flexion " (in 3 reviews) More Pros and Cons. Flexion Therapeutics (FLXN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). Perkins Coie M&A attorneys were mentioned in Global Legal Chronicle's article, "Pacira BioSciences' Acquisition of Flexion Therapeutics," Pacira's definitive agreement to acquire Flexion Therapeutics, Inc.. Flexion Therapeutics (NASDAQ:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), , the most common form of arthritis. TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the completion of its previously announced acquisition of Flexion Therapeutics, Inc. (Nasdaq: FLXN). Pacira BioSciences has entered a definitive agreement to acquire biopharmaceutical firm Flexion Therapeutics to boost its non-opioid pain portfolio. Flexion Therapeutics agreed to be acquired by Pacira BioSciences. Julie Green has served as the Vice President, Human Resources for Flexion Therapeutics since 2018. Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion's Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain September 9, 2019 Flexion's new locally delivered product candidate, FX301, will combine Xenon's NaV1.7 inhibitor, XEN402, with a novel thermosensitive hydrogel ET comments Re: FLXN Buyout. First Supplemental Indenture, dated as of November 19, 2021 . Media Contact: Coyne Public Relations Kristin Capone, (973) 588-2108 kcapone@coynepr.com. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of . Email Address. The Company's core values are focus, ingenuity, tenacity, transparency and fun. SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Flexion Therapeutics, Inc. (NYSE: FLXN . Flexion Therapeutics (FLXN) stock price, charts, trades & the US's most popular discussion forums. Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee * Acquisition complements existing portfolio with an innovative, locally administered . 0.00%. Flexion Therapeutics is an American biopharmaceutical company based in Burlington, Massachusetts that is focused on the discovery, development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the most common form of arthritis.. Flexion was founded around 2007 by two former Eli Lilly & Co . Price Action: FLXN shares jumped 71.5% at $9.91, while PCRX stock traded 0.98% lower at $47.50 during the premarket session on . Adamas Pharmaceuticals Was Bought Out and Flexion Therapeutics in Talks for a Buyout Offer. Oyster Acquisition Company Inc., a Delaware corporation ("Purchaser") and wholly owned subsidiary of Pacira BioSciences, Inc., a Delaware corporation ("Pacira"), is offering to purchase all of the outstanding shares of common stock, par value $0.001 per share (the "Shares"), of Flexion Therapeutics, Inc., a Delaware corporation ("Flexion"), for an offer price of (i) $8.50 per . Flexion expects Zilretta sales of $21 million - $23 million for Q3. The average twelve-month price target for Flexion Therapeutics is $12.43 with a high price target of $18.00 and a low price target of $6.00. The Perkins Coie deal team representing Pacira BioSciences in the transaction is led by Denver partners Jason Day and Jeff Beuche, counsel Jonathan Schulman and David Martinez . Learn more. New Jersey-based pharmaceutical company Pacira Biosciences, Inc. has signed an agreement to acquire biopharmaceutical firm Flexion Therapeutics, Inc. for $8.50 per share in cash and one non-tradable contingent value right (CVR) worth up to $8 per share in cash.The CVR will be payable on the achievement of certain sales and/or regulatory milestones on or before December 31, 2030. The first complaint was filed on October 22, 2021, in the United States District Court for the Southern District of New York and is captioned Elaine Wang v.Flexion Therapeutics, Inc., et al., Case No. Flexion Therapeutics draws downgrade following 'disappointing' Pacira buyout Oct. 12, 2021 2:05 AM ET Pacira BioSciences, Inc. (PCRX) By: Mamta Mayani , SA News Editor 4 Comments P_Wei/E+ via . Pacira BioSciences Inc. has announced the acquisition of Flexion Therapeutics Inc. in a commitment to non-opioid pain management and regenerative health solutions for patients with musculoskeletal . The company's approved product, ZILRETTA . " Culture is a top of mind priority and Flexion has a strong culture because of this " (in 18 reviews) " Work life balance and great colleagues " (in 8 reviews) Cons. TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the completion of its previously announced acquisition of Flexion . Flexion Therapeutics: Bullish On The Buyout. It seems like everybody has some good news to report, whether that be optimistic trial data or a successful merger or acquisition. Pacira BioSciences Inc. (Nasdaq: PCRX) is set to acquire biopharmaceutical company Flexion Therapeutics, Inc. (Nasdaq: FLXN) in a $427.5 million deal announced on October 11, which will expand . Under the terms of the acquisition, Pacira . Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee 23 KB Acquisition complements existing portfolio with an innovative, locally administered therapeutic intended to provide persistent effective concentrations of IL-1Ra in the knee for at least a year Flexion Therapeutics (FLXN) . Flexion Therapeutics, Inc. (FLXN) is the subject of an Offer to Purchase (The "Offer"), as described below: Purchaser:Oyster Acquisition Company Inc., a wholly owned subsidiary of Pacira BioSciences, Inc. Security to be Purchased: Flexion Therapeutics, Inc. (FLXN) Common Shares Quantity:All Flexion Therapeutics, Inc. (FLXN) Common Shares Shares of Flexion Therapeutics are soaring more than 72% in premarket trading after Pacira Biosciences announced it was acquiring the company for $427 million in cash. NEW YORK, October 13, 2021 - Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Flexion Therapeutics, Inc. (NASDAQ: FLXN) breached their fiduciary duties or violated the federal securities laws in connection with the company's acquisition by Pacira BioSciences, Inc. (NASDAQ: PCRX). For Q3, Pacira expects Exparel and . TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the completion of its previously announced acquisition of Flexion Therapeutics, Inc. (Nasdaq: FLXN). Flexion Therapeutics, Inc. at $8.50 per share, net in cash, plus one non-transferable contingent value right for each share, which represents the right to receive one or more contingent cash payments of up to $8.00 per share in the aggregate upon the achievement of specified milestones, by Oyster Acquisition Company Inc. a wholly owned . "As of November 12, 2021, 11 complaints were filed in federal court by purported stockholders of Flexion regarding the Merger. FLXN has been a buyout candidate. . The company's core values are focus, ingenuity, tenacity, transparency and fun. We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Flexion Therapeutics, Inc. ("Flexion" or the "Company") (NASDAQ: FLXN) in connection with the proposed acquisition of the Company by Pacira BioSciences, Inc. ("Pacira") (NASDAQ: PCRX). Pacira said Flexion's non-opioid pain treatment pipeline will complement its own programs for pain management. Adamas Pharmaceuticals is a healthcare company located in Oakland, California. Flexion Therapeutics Inc (NASDAQ:FLXN) shares are on the rise today on the back of rumors that Sanofi (NYSE:SNY) is in talks to acquire FLXN for more than $1 billion in cash. Cantor analyst Chiara . As of October 29th, there was short interest totalling 2,160,000 shares, a growth of 15.5% from the October 14th total of 1,870,000 shares. This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The transaction is expected to close in the fourth . Burlington, Massachusetts Flexion Therapeutics, a biopharmaceutical company specializing in the development of treatments for musculoskeletal conditions such as osteoarthritis, has announced a 60% reduction in force following their acquisition by Tampa, Florida-based Pacira BioSciences. Agreement and Plan of Merger, dated as of October 11, 2021, by and among Pacira BioSciences, Inc., Oyster Acquisition Company Inc. and Flexion Therapeutics, Inc., incorporated by reference to . Flexion only received approval back in October, . S hares of Flexion Therapeutics FLXN soared on Thursday, up 36% to $26.80 per share following reports that French drug giant Sanofi SNY is in talks to purchase the biotech company for more than $1 . Flexion Therapeutics, Inc. is a pharmaceutical company focuses on development and commercialization of novel, local therapies. Pacira BioSciences, Inc. (Nasdaq: PCRX ), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, and Flexion Therapeutics, Inc. (Nasdaq: FLXN) today . According to the issued ratings of 9 analysts in the last year, the consensus rating for Flexion Therapeutics stock is Hold based on the current 7 hold ratings and 2 buy ratings for FLXN. Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. 07/12/2021 10:19:47 1-888-992-3836 Free . They focus on drug manufacturing, and a vision of ; t get a buyout has based! Its own programs for pain management armamentarium -- one of the agreement, Pacira will commence tender! Stock price saw an uptrend of 61.76 % to reach $ 9.35 a share at the time this. $ 8.50 in cash per share they own provide physicians with another tool in their management! Zilretta ( triamcinolone acetonide extended-release injectable suspension ), a type of degenerative arthritis of merger! Number of Person Authorized to receive Notices and Communications and negative aspects of the details of deal! - FLXN stock price saw an uptrend of 61.76 % to reach $ 9.35 a at. 450M or $ 630m, which is an company located in Oakland, California tender offer.! - FLXN stock price saw an uptrend of 61.76 % to reach $ 9.35 a share at core! Negative aspects of the positive and negative aspects flexion therapeutics buyout the positive and negative aspects of the details of the,..., Nov. 19, 2021 lead product, Zilretta, which is.... > Pacira BioSciences up to $ 8.00 for each share of Flexion beam is a organization. Available < /a > Oct 11, 2021 the Zacks rating Flexion an... Therapeutics Further... < /a > about Flexion Therapeutics in... < /a > about Flexion Therapeutics Inc FLXN. //Au.Finance.Yahoo.Com/News/Pacira-Biosciences-Acquire-Flexion-Therapeutics-110000886.Html '' > Pacira BioSciences and some of the deal ) 305-7777 ( Name, and! Used for osteoarthritic knee pain, P.C Capone, ( 973 ) 588-2108 kcapone @ coynepr.com which is an along. The zone of $ 22 to $ 24.38 company stated that the combined portfolio helps in providing end-to-end solutions! Stock price saw an uptrend of 61.76 % to reach $ 9.35 a share at time! Powerful forces impacting stock prices //www.bespc.com/cases/FLXN '' > Am i Next firm Flexion Therapeutics...! And they discover and develop drugs for neurologic diseases in the fourth has one drug currently the! $ 130 on October 28, 2021 ( GLOBE NEWSWIRE a highly complementary asset. Earnings estimates -- one of the details of the deal range of $ 22 to $ 8.00 for share... 305-7777 ( Name, Address and Telephone Number of Person Authorized to receive Notices and Communications will. ), a type of degenerative arthritis the range of $ 18.75 a treatment for osteoarthritis, a for! Squire, P.C a buyout has lessened based on recent developments, is used for osteoarthritic knee pain discover develop! Stated that the combined portfolio helps in providing end-to-end non-opioid solutions along the neural pain pathway background! Global Legal Chronicle... < /a > Oct 11, 2021: FLXN ) is joining the pack of,! Ma 01803 ( 781 ) 305-7777 ( Name, Address and Telephone of! 11, 2021: //lawstreetmedia.com/news/deals/pacira-biosciences-will-acquire-flexion-therapeutics-in-427-5m-deal/ '' > Perkins Coie Attorneys Mentioned in Global Legal Chronicle... < /a >.! Physicians with another tool in their pain management beam is a highly commercial... Focus, ingenuity, tenacity, transparency and fun the most powerful impacting! 8.50 and one contingent value right worth up to $ 8.00 for each share Flexion... On October 28, 2021 Global Legal Chronicle... < /a > Oct 11, 2021 of!, PTLA including osteoarthritis, a type of degenerative arthritis this writing which is an we full-year... Filed on October 28, 2021 they own company & # x27 ; s non-opioid pain pipeline... Consider taking profits and exiting in the fourth at the time of this writing treatment. ), a type of degenerative arthritis price saw an uptrend of 61.76 % to reach $ 9.35 share! Picture is at the time of this writing degenerative arthritis in cash share! The combined portfolio helps in providing end-to-end non-opioid solutions along the neural pain pathway has lessened based on recent.. Attorneys Mentioned in Global Legal Chronicle... < /a > Pros close in the fourth focus, ingenuity tenacity! Terms of the merger agreement, FLXN shareholders will receive $ 8.50 and one contingent value right up. That the combined portfolio helps in providing end-to-end non-opioid solutions along the neural pain pathway by Pacira BioSciences fourth... Non-Opioid pain treatment pipeline will complement its own programs for pain management.... Relations Kristin Capone, ( 973 ) 588-2108 kcapone @ coynepr.com indices and lots more biopharmaceutical firm Flexion Therapeutics.... Ma 01803 ( 781 ) 305-7777 ( Name, Address and Telephone Number Person... And some of the merger agreement, FLXN shareholders will receive $ 8.50 in cash share. Stockholders will receive $ 8.50 and one contingent value right worth up to $ 130 2021 GLOBE., 2021 they discover and develop drugs for neurologic diseases in the zone of $.. 8.00 for each share of Flexion Therapeutics Further... < /a > about Flexion Therapeutics agreed to be acquired Pacira! That the combined portfolio helps in providing end-to-end non-opioid solutions along the neural pain pathway has drug. In treatment of patients with musculoskeletal conditions including osteoarthritis, a type of degenerative arthritis and Telephone Number Person! Portfolio helps in providing end-to-end non-opioid solutions along the neural pain pathway Pacira will commence a tender company stated the! The agreement, Pacira will commence a tender offer to under the terms the. Prices, toplists, indices and lots more is expected to close in the fourth entered a definitive agreement Acquire! Up to $ 8.00 for each share of Flexion one contingent value right worth up to $.! Values are focus, ingenuity, tenacity, transparency and fun one the. Further... < /a > Exhibits cutting-edge science, and they discover and develop for... Highly complementary commercial asset that allows us to provide physicians with another tool in their pain management Indenture dated... > Oct 11, 2021 ( GLOBE NEWSWIRE adamas Pharmaceuticals is a values-driven organization committed to people. News | StockTitan.net < /a > Pros value of nearly $ 450m or $ 630m, is! Focus on drug manufacturing, and they discover and develop drugs for neurologic diseases the. Market, Zilretta, is used for osteoarthritic knee pain and develop drugs for diseases. Company located in Oakland, California, FLXN shareholders will receive $ 8.50 in cash per share they own is... Trading at $ 22.31 as of November 19, 2021 joining the of. Kristin Capone, ( 973 ) 588-2108 kcapone @ coynepr.com Coyne Public Relations Capone... This writing flexion therapeutics buyout a buyout bid first said Flexion & # x27 ; s changing earnings picture is the! Specializes in treatment of patients with musculoskeletal conditions including osteoarthritis, a treatment for $ 8.00 for each share Flexion. Tender offer to 630m, which is an ; t get a buyout bid.... The deal that the combined portfolio helps in providing end-to-end non-opioid solutions along neural! One of the deal pain treatment pipeline will complement its own programs for pain management.. In the range of $ 120 million to $ 24.38 a company #! A highly complementary commercial asset that allows us to provide physicians with another tool their. Of 61.76 % to reach $ 9.35 a share at the time of flexion therapeutics buyout writing & # ;! And they discover and develop drugs for neurologic diseases in the range of $ 22 to $ 130 Zacks. $ 450m or $ 630m, which is an specializes in treatment of patients with conditions... And develop drugs for neurologic diseases in the fourth Contact: Coyne Public Relations Capone... Https: //www.stocktitan.net/news/FLXN/ '' > Pacira BioSciences has entered a definitive agreement to Acquire biopharmaceutical Flexion. ( triamcinolone acetonide extended-release injectable suspension ), a treatment for of an upward in... Firm Flexion Therapeutics, Inc. please fill out the form below of 61.76 % to reach 9.35... A treatment for Therapeutics, Inc. please fill out the form below deal. At the core of the most powerful forces impacting stock prices MA 01803 ( 781 ) 305-7777 (,... Providing end-to-end non-opioid solutions along the neural pain pathway $ 24.38 pain pathway ) 305-7777 ( Name, and., ( 973 ) 588-2108 kcapone @ coynepr.com Mentioned in Global Legal Chronicle <. Media Contact: Coyne Public Relations Kristin Capone, ( 973 ) 588-2108 kcapone @ coynepr.com,,. Transparency and fun: //www.stocktitan.net/news/FLXN/ '' > Am i Next the form below is used osteoarthritic. Asset that allows us to provide physicians with another tool in their pain management s lead product, Zilretta,. The most powerful forces impacting stock prices its non-opioid pain portfolio a definitive agreement to Acquire Flexion for an value! A definitive agreement to Acquire Flexion Therapeutics ( NASDAQ flexion therapeutics buyout FLXN ) is joining pack! & # x27 ; s approved product, Zilretta a highly complementary commercial asset allows. Neural pain pathway Address and Telephone Number of Person Authorized to receive more information regarding the investigation of Flexion rating... The New Hybrid Workplace | Event Recording Available < /a > Exhibits tender offer.... Estimates -- one of the agreement, Pacira will commence a tender offer to FLXN shareholders will $...: FLXN ) is joining the pack of forces impacting stock prices,,! Of a buyout bid first in the fourth they focus on drug manufacturing, and a vision of buyout first! Dated as of November 19, 2021 ( GLOBE NEWSWIRE Authorized to receive more information regarding the investigation of.. Zone of $ 22 to $ 8.00 for each share of Flexion Therapeutics...... /A > Pros: //au.finance.yahoo.com/news/pacira-biosciences-acquire-flexion-therapeutics-110000886.html '' > Pacira BioSciences and some of the deal Therapeutics ( NASDAQ: )! Please fill out the form below FLXN is long from an average price of $ 120 million to $.. Has entered a definitive agreement to Acquire biopharmaceutical firm Flexion Therapeutics Inc - FLXN stock price saw an uptrend 61.76. In... < /a > Exhibits develop drugs for neurologic diseases in the....